Medicare beneficiaries who depend on insulin will keep paying no more than $35 for a one-month supply of each covered insulin product in 2027, under both Part D prescription plans and Part B coverage for insulin pump users. The Centers for Medicare and Medicaid Services is now writing that cap into permanent regulation as temporary program instruction authority expires, a shift that locks the price ceiling into the federal rulebook but also raises questions about how plan sponsors will shape their formularies in response.
Why the $35 insulin cap carries new weight for 2027 enrollment
The Inflation Reduction Act set the $35 monthly copayment ceiling starting in plan year 2023, and federal statute extends it through 2026 and each subsequent plan year. That statutory language, codified in Part D law, defines the “applicable copayment amount” as $35 or less for a one-month supply of each covered insulin product under Part D. For beneficiaries who receive insulin through durable medical equipment pumps under Part B, a parallel provision in Section 1395l caps coinsurance at the same $35 threshold for insulin furnished on or after July 1, 2023.
What changes for 2027 is not the dollar figure but its regulatory footing. CMS is converting what had been program instructions into codified rule text through its 2027 final rule. That transition matters because program instructions can be revised through internal agency guidance, while codified regulations carry the weight of the federal rulemaking process and are harder to reverse.
The practical tension sits with Part D plan sponsors. The $35 cap applies per covered insulin product, meaning a beneficiary who fills two different insulin prescriptions in the same month pays no more than $35 for each. Plan sponsors absorb the difference between the capped copayment and the actual cost of the drug. As CMS locks the cap into permanent regulation alongside broader Part D redesign changes, sponsors face a fixed revenue ceiling on insulin cost-sharing while their total liability for insulin spending remains variable.
That dynamic creates a strong incentive for at least some sponsors to narrow the list of preferred insulin products on their 2027 formularies. By concentrating covered insulin options around products with favorable rebate agreements, plans can reduce their per-unit cost exposure without violating the $35 cap. Beneficiaries would still pay $35 or less, but they could find fewer insulin brands or formulations on their plan’s preferred tier.
Statutory and regulatory evidence behind the permanent cap
The legal architecture supporting the 2027 cap rests on two sections of the U.S. Code. Under Part D, the applicable copayment amount for a one-month supply of each covered insulin product cannot exceed $35, a provision the Congressional Research Service confirmed in its analysis of Section 11406 of Public Law 117-169. The CRS described the cap as an “applicable copayment amount” designed to reduce out-of-pocket costs for insulin users across Medicare, according to its legislative summary of the law’s health care provisions.
On the Part B side, the statute requires adjustments for insulin furnished through DME so that a beneficiary’s coinsurance for a month’s supply does not exceed $35. That provision took effect for insulin furnished on or after July 1, 2023, according to the statutory text in 42 U.S.C. Section 1395l. Official Medicare consumer guidance confirms the same rule in plain language: if a beneficiary uses a covered insulin pump under Part B, the cost for a month’s supply of Part B-covered insulin for that pump cannot exceed $35, consistent with the agency’s description of Part B coverage.
CMS is now folding these IRA-directed Part D changes into permanent regulation because the agency’s temporary program instruction authority is expiring. The Contract Year 2027 final rule covers this transition alongside other Part D redesign elements, including how plans must apply cost-sharing caps at the point of sale and reconcile them with new liability structures in the benefit phases. The CRS separately confirmed that the IRA established the insulin cost-sharing cap policy across both Parts D and B as part of its broader Medicare drug pricing provisions.
Open questions about formulary design and beneficiary access in 2027
Several gaps in the public record leave real uncertainty about how the permanent cap will play out for individual beneficiaries. No official CMS data projects how many people will use each covered insulin product in 2027, and no published list identifies the exact insulin products that will qualify as “covered” under the cap for that plan year. Without that information, beneficiaries cannot yet confirm whether their current insulin will remain on a preferred formulary tier.
Plan formulary filings for 2027 have not been made public in a form that shows how Medicare Advantage and Part D sponsors intend to balance the capped copayment against other redesign changes taking effect the same year. The broader Part D restructuring alters how costs are shared among beneficiaries, plans, and manufacturers, and insulin formulary decisions will reflect those shifting economics. CMS has not released beneficiary-level data on cost offsets or medication adherence outcomes tied specifically to the insulin cap provisions, which means the policy’s real-world performance is still largely inferred from aggregate spending and utilization trends rather than direct measurement.
That lack of granular data complicates oversight. Policymakers and advocates cannot easily distinguish between benign formulary consolidation-such as steering toward clinically similar biosimilars with lower net prices-and more aggressive narrowing that might disrupt stable treatment regimens. Without transparent reporting on prior authorization rates, step therapy requirements, or midyear formulary changes affecting insulin, it will be difficult to assess whether the permanent cap is being implemented in a way that preserves meaningful choice for patients.
There is also uncertainty around how plans will coordinate insulin coverage across Parts B and D for beneficiaries who use multiple delivery methods. Some enrollees may receive one type of insulin through a pump covered under Part B and another through prefilled pens or vials under Part D. While the statute and regulations require that each month’s supply be capped at $35 under the applicable part, there is limited public guidance on how plans will communicate these distinctions to beneficiaries or manage transitions when a prescriber recommends switching from one delivery system to another.
What beneficiaries should watch as 2027 nears
For now, the most concrete takeaway for Medicare beneficiaries is that the $35 monthly limit for each covered insulin product will remain in place and will be backed by formal regulation rather than temporary guidance. That stability may offer some reassurance to people who have already seen their out-of-pocket insulin costs drop under the Inflation Reduction Act’s provisions.
Still, the permanence of the cap does not eliminate the need for careful plan comparison during open enrollment. Beneficiaries and counselors will need to look closely at 2027 formularies to see which insulin products are covered, on which tiers, and with what utilization management requirements. Even with a uniform $35 ceiling, differences in brand availability and administrative hurdles could make some plans more attractive than others for people who rely on specific insulin regimens.
As CMS implements the Contract Year 2027 final rule, further guidance or data releases could clarify how plans are adapting their formularies and what that means for access. Until then, the policy story is split between a clear statutory promise-a $35 monthly maximum for each covered insulin product under Parts B and D-and a less clear operational reality, in which plan-level decisions will determine how straightforward it is for beneficiaries to obtain the insulin their clinicians prescribe.
Free tool for readers: Built for Americans 55 to 80: a free, plain-English retirement check. See your Retirement Safety Score — your 0–100 number and a few steps — in about five minutes, no account needed.
